



Trial Information Summary

ALLG Trial Number:	MM19
Trial Name: A Phase 3 trial of thalidomide-dexamethasone consolidation versus thalidomide-dexamethasone-ixazomib consolidation for transplant eligible multiple myeloma patients undergoing a single ASCT as part of front-line therapy	
Lay Summary: This study will determine whether the addition of the oral proteasome inhibitor ixazomib prolongs the duration of myeloma disease control when added to standard post autologous consolidation with thalidomide and corticosteroids.	
Participating Hospitals: 1. Alfred	
Target Accrual (International):	n/a
Target Accrual (ALLG):	310 (Registered); 280 (Randomised)
Expected Final Accrual Date:	2020